Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017096031) METHODS OF ASSOCIATING GENETIC VARIANTS WITH A CLINICAL OUTCOME IN PATIENTS SUFFERING FROM AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTI-VEGF
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/096031 International Application No.: PCT/US2016/064403
Publication Date: 08.06.2017 International Filing Date: 01.12.2016
IPC:
C12Q 1/68 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
68
involving nucleic acids
Applicants:
REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road Tarrytown, NY 10591, US
Inventors:
PERLEE, Lorah; US
HAMON, Sara; US
Agent:
LEGAARD, Paul K.; US
Priority Data:
62/262,58903.12.2015US
62/291,27404.02.2016US
Title (EN) METHODS OF ASSOCIATING GENETIC VARIANTS WITH A CLINICAL OUTCOME IN PATIENTS SUFFERING FROM AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTI-VEGF
(FR) MÉTHODE D'ASSOCIATION DE VARIANTES GÉNÉTIQUES À UN RÉSULTAT CLINIQUE CHEZ DES PATIENTS SOUFFRANT DE DÉGÉNÉRESCENCE MACULAIRE LIÉE À L'ÂGE ET TRAITÉE PAR ANTI-VEGF
Abstract:
(EN) Methods for associating a genetic variant with intraretinal fluid as a marker for response to therapy with anti-VEGF in age-related macular degeneration (AMD). Disclosed herein are further methods for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency. The genetic variants identified are found in a gene-free region on chromosome X p.22.3, in the MECOM gene, in the NTRK3 gene and in the ANK2 gene.
(FR) L'invention concerne des méthodes permettant d'associer une variante génétique à un fluide intrarétinien comme marqueur pour la réaction au traitement par anti-VEGF dans une dégénérescence maculaire liée à l'âge (DMLA). L'invention concerne également des méthodes permettant d'associer une variante génétique à l'acuité visuelle, à des résultats anatomiques ou à une fréquence de traitement. Les variantes génétiques identifiées sont trouvées dans une région exempte de gène sur le chromosome X p.22.3, dans le gène MECOM, dans le gène NTRK3 et dans le gène ANK2.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
CA3007276AU2016364817IL259672KR1020180081616CN108474039EP3384049